Table 4 Univariate analysis of NCI vs. PSCI subjects in the model external validation cohort from the STRIDE Study.

Stroke to follow-up interval, mean (SD), mo

5.03 (1.39)

5.14 (1.19)

0.183

Age, mean (SD) [range], y

65.60 (10.22) [37–95]

75.28 (9.73) [37–96]

<0.001*

Gender, No. (%), female

105 (30.8%)

200 (56.8%)

<0.001

Education, median (IQR), y

7.0 (5.0)

3.0 (6.0)

<0.001*

NIHSS score, median (IQR)

3.0 (4.0)

5.0 (5.0)

<0.001*

Diabetes mellitus, No. (%)

106 (31.1%)

154 (42.9%)

0.001*

Hypertension, No. (%)

226 (66.3%)

259 (73.6%)

0.036*

Hyperlipidemia, No (%)

234 (68.6%)

217 (61.7%)

0.054

Atrial fibrillation, No (%)

48 (14.1%)

76 (21.7%)

0.009*

History of smoking, No. (%)

156 (46.3%)

128 (37.1%)

0.015*

History of drinking, No. (%)

50 (15.1%)

19 (5.5%)

<0.001*

History of TIA, No. (%)

10 (3.0%)

6 (1.7%)

0.281

History of stroke, No. (%)

53 (15.5%)

87 (24.7%)

0.003*

History of IHD, No. (%)

28 (8.4%)

43 (12.3%)

0.089

Family history of stroke, No. (%)

11 (3.2%)

4 (1.1%)

0.059

Victoroff global score, median (IQR)^†

0.0 (1.0)

0.0 (2.0)

0.015*

ARWMC global score, median (IQR)^†

1.0 (2.0)

2.0 (3.0)

<0.001*

   Cortical

32 (9.4%)

29 (8.2%)

0.595

   Sublobar

132 (38.7%)

127 (36.1%)

0.474

   Infratentorial

54 (15.8%)

45 (12.8%)

0.251

   Cortical

21 (6.2%)

42 (11.9%)

0.008*

   Sublobar

25 (7.3%)

38 (10.8%)

0.113

   Infratentorial

16 (4.7%)

13 (3.7%)

0.511

 Presence of chronic lacunes, No. (%), total^†

166 (48.7%)

237 (67.3%)

<0.001*

 Presence of microhemorrhages, No. (%), total^{†, ‡}

44 (62.9%)

40 (76.9%)

0.097

   MMSE, median (IQR)^§

28.0 (2.0)

21.0 (8.0)

—

   MoCA, median (IQR)^§

25.0 (4.0)

15.0 (7.5)

—

   GDS, median (IQR)

3.0 (6.0)

5.0 (6.0)

<0.001*

   CDR SoB, median (IQR)

0.0 (0.5)

1.0 (3.0)

<0.001*